Protalix BioTherapeutics Overview
Valuation check: PLX's P/E ratio is 11.24, below the Healthcare sector average of 25.72.
Get informed when a big investor buys or sells
+ Follow11.24
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, PLX shows a P/E ratio of 11.24. That is below the Healthcare sector average of 25.72. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 25.72. Protalix BioTherapeutics is at 11.24, which is lower that average. That is roughly 56.3% below the sector mean. Use the comparison chart on this page to see how PLX stacks up against individual peers as well.
Investors watch PLX's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Protalix BioTherapeutics's latest reading is 11.24. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Protalix BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 11.24) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 25.72, while PLX is at 11.24. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
